Market Overview - On January 9, the Hang Seng Index rose by 0.32% to close at 26,231.79 points, while the Hang Seng Tech Index increased by 0.15% to 5,687.14 points [1][2]. - The total trading volume for the Hang Seng Index was 245.1 billion, and for the Hang Seng Tech Index, it was 69.3 billion [2]. Company Highlights - MiniMax, a large model company, debuted on the Hong Kong Stock Exchange with an issue price set at the upper limit of the range, at 165 HKD per share. The stock opened with a gain of over 50% and closed with a total increase of 109.09%, reaching 345 HKD per share, with a trading volume of 4 billion HKD and a total market capitalization exceeding 100 billion HKD [2]. Sector Performance - In the tech sector, stock performances varied: Alibaba Health rose by over 4%, Tencent Music, Kuaishou, and Bilibili increased by over 3%. Conversely, BYD Electronics, Meituan, and Baidu Group saw declines of over 2% [4][5]. - Notable stock movements included: - Alibaba Health: 5.770 HKD, +4.72% - Tencent Music: 68.700 HKD, +3.93% - Kuaishou: 74.700 HKD, +3.89% - BYD Electronics: 34.300 HKD, -2.56% - Meituan: 98.500 HKD, -2.48% - Baidu Group: 137.400 HKD, -2.07% [5]. Commodity and Sector Trends - The non-ferrous metals and oil & petrochemical sectors experienced gains, with Shandong Gold rising over 6%. In contrast, the photovoltaic sector faced significant declines, with New Energy dropping over 8% and GCL-Poly Energy falling over 7% [4].

Core Insights - JD Health is set to enhance its investment in the medical device sector, focusing on supply, AI, and medical services as core drivers for growth, aiming to become a significant growth engine and launchpad for global medical device brands by 2026 [1][5] Group 1: Strategic Initiatives - JD Health signed agreements with 100 global brands to launch new products in 2026, committing over 100 million in marketing resources to ensure that new products are launched as bestsellers [1][5] - The company aims to create a comprehensive ecosystem that meets user needs across all channels and life cycles, supporting the "Healthy China 2030" strategy [1] Group 2: Market Growth and Product Innovation - The medical device market in China is projected to grow from approximately 300 billion to 500 billion, driven by aging population, health awareness, and consumption upgrades [3] - JD Health plans to deepen global collaborations and enhance domestic supply through initiatives like JDH+N alliance, targeting a 100% growth in trending categories [3] Group 3: Awards and Recognition - JD Health established a rigorous evaluation system for awarding the 2025 Golden Award for new medical devices, recognizing nearly 100 brands for their quality and reputation [5] Group 4: AI and Service Integration - JD Health is leveraging its self-developed AI model "Jingyi Qianxun" to transform product categories and define value through services, moving towards a full-cycle health management solution [7] - The company has launched customized CGM products in collaboration with brands like Yuyue and Sanofi, creating an integrated smart blood glucose management system [9] Group 5: Consumer Engagement and Service Enhancement - JD Health's AI doctor "Xiao Wei" provides comprehensive support throughout the purchasing process, achieving a user satisfaction rate of 98.4% [9] - The company is enhancing its online and offline medical services, integrating them with medical device usage scenarios to create a seamless health management experience [9]

Core Insights - JD Health is significantly increasing its investment in the medical device sector, leveraging its robust supply chain, AI technology, and internet healthcare services to build a comprehensive ecosystem that meets the full lifecycle needs of users [1][2] - The medical device market is expanding rapidly as health awareness rises, consumer demands become more refined, and the aging population accelerates, creating a vast market with immense potential [1] - JD Health aims to transition the industry from reactive treatment to proactive health management, injecting strong momentum and innovation into the sector [1] Company Strategy - JD Health is committed to long-term investment in the medical device category, positioning itself as a powerful growth engine and launch platform for brands [2] - The company plans to deepen the integration of online consultations, home testing, and home care services with medical device usage scenarios, while expanding AI applications and building an interconnected smart ecosystem [2] - A strategic focus for 2026 includes slow disease management, home elder care, home-use medical products, and wellness products, with over 100 million yuan allocated for marketing new medical device products [3] Financial Performance - JD Health reported impressive growth in its latest financial results, with revenues of 17.12 billion yuan for Q3 2025, marking a year-on-year increase of 28.7%, and a non-IFRS net profit of 1.9 billion yuan, up 42.4% [3]

Core Insights - JD Health is leveraging its internet hospital to enhance medical device brand growth and user health management in the rapidly developing internet healthcare sector [1][2] Group 1: Market Overview - The internet healthcare market in China is projected to reach 479.9 billion yuan by 2025, with user numbers exceeding 400 million [2] - JD Internet Hospital, one of the first licensed independent internet hospitals, maintains its position as the "first entry point for online diagnosis," with over 500,000 daily consultations and a customer satisfaction rate of 98.9% [2] Group 2: Service Innovations - JD Internet Hospital has established a comprehensive service system covering "medical, testing, diagnosis, and medication," allowing users to complete the entire diagnostic process from home [2] - The hospital is enhancing its specialized service system, with upgrades in dermatology, mental health, and traditional Chinese medicine, and plans to add urology and oncology specialties by 2025 [2] Group 3: Case Study and User Experience - A case study illustrates a patient with chronic obstructive pulmonary disease and myocardial infarction receiving comprehensive care through JD Internet Hospital, including video consultations, home delivery of a respiratory machine, and ongoing remote monitoring by healthcare professionals [3] Group 4: Ecosystem Collaboration - JD Internet Hospital supports medical device brands through a full-chain support system, including doctor communication, user management, and hospital scene engagement [4] - The hospital employs a team of health managers and nutritionists, utilizing smart operational tools to provide comprehensive health management, achieving a 59% repurchase rate for a specific medical food brand [4] Group 5: Future Directions - JD Internet Hospital aims to build trust between patients and brands, focusing on data and services for long-term health management [5] - The hospital plans to continue service innovation and specialized construction, collaborating with partners to advance the healthcare industry towards greater efficiency and warmth, contributing to the "Healthy China" initiative [5]

Core Insights - JD Health's internet hospital has achieved a daily consultation volume exceeding 500,000, with a customer satisfaction rate of 98.9% [1][3] Group 1: Service Expansion - JD Health is enhancing its specialized service system, having upgraded its dermatology, mental health, and traditional Chinese medicine departments, with plans to add urology and oncology specialties by 2025 [1][3] - The company has established a comprehensive service model covering "medical, testing, diagnosis, and medication," allowing users to complete the entire diagnostic process from home [1][3] Group 2: Future Developments - By 2025, JD Health plans to further expand the integration of medical services and medical devices [1][3] - The company has developed a full support system for medical device brands, including communication with doctors, user management, and hospital scene engagement [1][3] Group 3: User Management and Research Support - JD Health utilizes its team of health managers and nutritionists, along with intelligent operational tools, to provide comprehensive health management for users [2][4] - The company is exploring online hospital scene integration through DTP services and public welfare projects, facilitating brand engagement in both hospital and external settings [2][4] - JD Health offers a digital research platform for medical device companies, enhancing clinical research efficiency through intelligent follow-up and data collection tools [2][4]

Core Insights - JD Health is set to enhance its medical device sector by leveraging supply chain, AI, and medical services as core drivers, aiming to become a significant growth engine for global medical device brands by 2026 [1][5] - The company plans to invest over 100 million in marketing resources for the launch of new products in collaboration with top global brands, focusing on high-quality development in the medical device industry [1][5] Group 1: Market Growth and Strategy - The medical device market in China is experiencing rapid growth, projected to reach 500 billion from the current 300 billion, driven by aging population, health awareness, and consumption upgrades [3] - JD Health aims to deepen partnerships with global medical device brands and enhance supply chain capabilities through initiatives like JDH+N alliance, targeting a 100% growth in trending categories by 2025 [3][6] Group 2: Product Innovation and Awards - In 2025, JD Health launched nearly 500 new products, setting industry records, with a focus on innovative product development as a key driver for high-quality growth [3][5] - The company established a rigorous evaluation system for product awards, recognizing nearly 100 brands for their quality and reputation at the annual conference [5] Group 3: AI and Service Integration - JD Health is utilizing its self-developed AI model "Jingyi Qianxun" to transform product categories and define value through service, moving towards comprehensive health management solutions [6][7] - The company has developed a smart blood glucose management system in collaboration with brands, integrating monitoring, analysis, intervention, and tracking for chronic disease management [9] Group 4: Comprehensive Health Management - JD Health is enhancing its online and offline service integration, providing a full-cycle health management experience that includes disease prevention, smart monitoring, chronic disease management, and post-hospital rehabilitation [9] - The company aims to eliminate homogenization in the medical device industry through product innovation and AI technology upgrades, making professional healthcare services more accessible [9]

此次京东健康全网首发的盐酸普萘洛尔口服溶液(合美嘉®)，是一种含有普萘洛尔的创新药。2018年， 科福新药获得盐酸普萘洛尔口服溶液原研企业、全球第二大皮肤学护肤品集团法国皮尔法伯(Pierre- Fabre)的认可，产品适应症专利在中国范围内的独占许可授权给武汉科福新药，授权其在中国独家研发 及上市盐酸普萘洛尔口服溶液。这也是我国首个获批上市治疗婴幼儿血管瘤(infantile hemangioma，IH) 的专利新药，填补了国内临床用药空白。 合美嘉®处方辅料与原研药完全一致，适口性、有关杂质纯度水平也接近原研药，并符合相关质量要求 和标准。产品模拟使用2个月，稳定性良好，性状、颜色、pH值、有关物质及含量均无明显变化。此 外，合美嘉®与牛奶、果汁相容性好，可以通过混合给药，使口服液更容易入口，减少患儿用药不便。 1月8日，针对婴幼儿血管瘤的创新型口服治疗药物——盐酸普萘洛尔口服溶液(合美嘉®)在京东健康线 上首发，为患儿治疗提供更多选择。患者通过京东APP搜索"合美嘉"即可在线咨询医生、进行购买。 婴幼儿血管瘤也被称为"天使之吻"，是婴幼儿最常见的良性血管肿瘤，发病率约为2.2%，且呈逐年升高 趋势。其中 ...

1月8日，科瑞德制药旗下原研创新药盐酸替扎尼定口服溶液（商品名：凯莱通®）在京东健康全网首 发，为疼痛与肌肉紧张患者带来全新治疗选择。京东健康也将发挥"新特药线上首发第一站"的领先优 势，帮助合作伙伴将凯莱通®触达更多患者。 区别于传统非甾体抗炎药（NSAIDs）仅聚焦炎症和疼痛本身，凯莱通®通过激动中枢α₂肾上腺素受 体，作用更全面，实现"止痛+肌松"双重作用，有效打破"疼痛—肌紧张—循环障碍—再疼痛"的恶性循 环。 在安全性方面，凯莱通®展现出显著优势。临床研究证实，其可连续使用长达13周以上，远超传统 NSAIDs通常7天的用药限制；且低剂量治疗时不良反应轻微、短暂。与同类肌松药相比，凯莱通®作用 更全面，安全性更高，不影响正常肌力，无全身乏力或跌倒风险；无撤药反应，避免了幻觉、癫痫等严 重副作用。更关键的是，它不伤胃，可保护胃粘膜，与NSAIDs联用时，形成"肌松+抗炎+镇痛"的黄金 组合，协同增效的同时可抵消NSAIDs常见的胃肠道不良反应。 凯莱通®作为科瑞德制药的拳头产品，历经20余年沉淀，始终坚持以患者为中心，现已成为四川知名品 牌和居家必备的常用药。未来，京东健康将联手科瑞德制药，持续推动凯 ...

Market Overview - The Hong Kong stock market continued its downward trend on January 8, with the Hang Seng Index and Hang Seng Tech Index both falling over 1% [1][9] - Major tech stocks such as Meituan, Alibaba, and Tencent experienced declines, while Bilibili saw a rise of over 2% [1][9] - The Hong Kong Internet ETF (513770) closed down 0.93%, indicating a persistent premium and a positive attitude from buyers, with over 500 million yuan net inflow in the last three days [1][9] Alibaba Developments - Alibaba announced significant progress in its Taobao Flash Sales in the latest quarter and plans to increase investments to achieve market leadership [3][11] - Forecasts suggest that the market share of Taobao Flash Sales will continue to grow strongly by Q4 2025, with a faster reduction in losses compared to competitors [3][11] - The Ministry of Commerce predicts that China's instant retail market will exceed 1 trillion yuan by 2026 and reach 2 trillion yuan by 2030 [3][11] AI Advancements - Alibaba's Amap has upgraded its "Street Scanning List" with new features, leveraging self-developed world model technology to introduce a "Flying Street View" function [3][11] - Industry experts believe Amap is building a continuously evolving "true" digital asset pool, positioning itself as a super hub in the AI era [3][11] - The profitability cycle of the AI industry is expected to drive growth for major internet companies like Alibaba and Tencent, with a projected 34% EPS growth for the Hang Seng Tech Index by 2026 [3][11] Capital Inflows - Since the beginning of the year, southbound funds have significantly purchased Hong Kong stocks, with a net inflow of 30.78 billion HKD in the first three trading days of 2026 [4][12] - Major beneficiaries include Xiaomi, which received a net inflow of 3.148 billion HKD, and Alibaba, which saw over 2 billion HKD in net purchases [4][12] - Goldman Sachs forecasts that southbound fund inflows will reach a new high of 200 billion USD in 2026, driven by the current 37% premium of AH shares, highlighting the valuation advantages of Hong Kong stocks [4][12] Market Outlook - According to Guangfa Securities, the rise in Hong Kong assets is supported by fundamentals, with signs of structural recovery in profitability starting from the second half of 2024 [4][12] - The shift from liquidity-driven growth to a combination of profitability and liquidity is anticipated, especially with the decline of food delivery subsidies and the emergence of AI-driven advertising and cloud services as new growth points [4][12] - The Hong Kong Internet ETF and its linked funds track the CSI Hong Kong Internet Index, with major holdings in Alibaba, Tencent, and Xiaomi, accounting for over 78% of the top ten weighted stocks [4][12] Top Holdings in Hong Kong Internet ETF - Tencent Holdings (0700.HK) - 15.42% [5][13] - Alibaba (0988.HK) - 14.50% [5][13] - Xiaomi Group (1810.HK) - 13.11% [5][13] - Meituan (3690.HK) - 12.03% [5][13] - Kuaishou (1024.HK) - 4.24% [5][13]

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 | 代码 名称 | | 12月复权单位 累计单位 | | | --- | --- | --- | --- | | | 净值增长率8 净值元 | | | | 513060. SH 博时恒生医疗保健(QDII-ETF) | -10.17 | 0.59 | 63.02 2021-03-18 万琼 | 来源：同花顺 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@s ...